Htg Molecular Diagnostics, Inc
Molecular diagnostic platform for gene expression analysis using microfluidic technology
- Sector
- Biotech
- Headquarters
- AZ
- Latest Form D
- $7.5M, Mar 2022
- Total capital
- $38.9M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $37.7M
- 8 Form D · last Mar 2022
- 55 months since last filing
- Federal contracts
- $1.2M
- 28 awards · Health and Human S, Veterans Affairs, Defense
- Rank in Biotech#178 of 4373
- Granted patents
- 5
- 19 pending · first 2016
- Rank in peer group#2 of 32
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 8th filing$7.5M
- Federal contractHealth and Human S · Laboratory Testing Services$21K
- Federal contractVeterans Affairs · Oncology Biomarker Tests$63K
- Federal contractAgriculture · Htg Molecular Lab Services$158K
- Private capital raisedForm D · SEC · 7th filing$3.5M
- Federal contractHealth and Human S · Lab Services, Mirna Analysis For Set Of 58 Samples Catalog#: SP-ES-01$14K
- Federal contractHealth and Human S · Mouse Microrna (mirna) Whole Transcriptome Assays$17K
- Offering registeredForm D · SEC · 6th filing$18M
- Offering registeredForm D · SEC · 5th filing$800K
- Private capital raisedForm D · SEC · 4th filing$7.5M
- Private capital raisedForm D · SEC · 3rd filing$7.6M
- Private capital raisedForm D · SEC · 2nd filing$10M
- Private capital raisedForm D · SEC · 1st filing$1.7M
Show 21 earlier federal awards
- Federal contractHealth and Human S · Drugs And Biologicals$9K
- Federal contractEnvironmental Prot · Custom Array Plate$20K
- Federal contractEnvironmental Prot · Arrayplate Service$10K
- Federal contractVeterans Affairs · Gene Array$24K
- Federal contractEnvironmental Prot · Custom Array Development$15K
- Federal contractDefense · Custom Array Development, Mirna Assays, 96 Well / 47 Genes$14K
- Federal contractDefense · Supercapella Imaging System And Service Agreement$31K
- Federal contractHealth and Human S · Service Agreement For Supercapella Reader$4K
- Federal contractHealth and Human S · TAS::75 0849::TAS Small Business Innovative Research (SBIR) Topic 283$150K
- Federal contractHealth and Human S · TAS::75 0862::TAS Qfix Arrayplate -- Housekeeping Gene Analysis, 1-10 Samples Cat. # 701-101$61K
- Federal contractVeterans Affairs · Ffpe Gene Array-bases Lab Testing$202K
- Federal contractHealth and Human S · TAS::75 0862::TAS SBIR 2010 Topic 109$149K
- Federal contractVeterans Affairs · Array Implementation Of Quantitative Nuclease Project Assay (qnpa) Arrays For Gene Expression Analysis In Non-small Lung Cancer$30K
- Federal contractHealth and Human S · 00000HCV-2010-79612 - H1N1 Pgo# 1323 Fmo# 1193$52K
- Federal contractVeterans Affairs · 2040 Gene Custom Array Oligo And Quality Control Test$30K
- Federal contractHealth and Human S · Catalog# 700-014ARRAY Design And Production Collaboration Array, Reagents, Services For Developing 1 96-WELL Plate Assay Of Up To 27 Target Transcripts POTS#09-010005$10K
- Federal contractHealth and Human S · Arrays$19K
- Federal contractVeterans Affairs · 2040 Gene Custom Array Development And Design Services$42K
- Federal contractHealth and Human S · High Throughput Genomics - Custom Array/ Plates Kit (reagents And Plates) Thorsell$6K
- Federal contractHealth and Human S · Development Of 15-PLEX Custom Htg Arrayplate Array: NIH-2. Quote # NIH-080228. Deliver To Klaus Pechhold, Bldg 10CRC, Rm 5-5940. Purchasing Agent: Emily Wertz, 301-594-3947.$13K
- Federal contractHealth and Human S · Covering Order Number Five For Purchase Of Assay Development Services: 96 Well Plates With 7 Genes$8K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
2 records have no date or no amount, so they aren’t placed on the timeline.
Federal first
29months
from Htg Molecular Diagnostics, Inc’s first federal award to its first private round.
- First federal award · Mar 2008
- Health and Human S · $8K
- First Form D · Aug 2010
- $1.7M · 1st Form D
- Awards before first raise
- 11 awards
An association in public records, not a cause or a prediction.
Standing among 32 peers
Line = medianBiotech · Device
- Granted patents#2 · top 6%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Ann F. HanhamDirectorNamed in SEC Form D filings
- Ann F. HanhamDirectorNamed in SEC Form D filings
- Christopher KiritsyDirectorNamed in SEC Form D filings
- Donald W. GrimmDirectorNamed in SEC Form D filings
- Don M. HardisonDirectorNamed in SEC Form D filings
- Don M. HardisonDirectorNamed in SEC Form D filings
Show all 24 people
- Harry A. GeorgeDirectorNamed in SEC Form D filings
- Harry GeorgeDirectorNamed in SEC Form D filings
- James T. LaFranceDirectorNamed in SEC Form D filings
- James T. LaFranceDirectorNamed in SEC Form D filings
- Jim WeersingDirectorNamed in SEC Form D filings
- John LubniewskiExecutive Officer, DirectorNamed in SEC Form D filings
- Kirk A. CollamerExecutive OfficerNamed in SEC Form D filings
- Larry SenourDirectorNamed in SEC Form D filings
- Lee R. McCrackenDirectorNamed in SEC Form D filings
- Lee R. McCrackenDirectorNamed in SEC Form D filings
- Lewis ShusterDirectorNamed in SEC Form D filings
- Michelle R. GriffinDirectorNamed in SEC Form D filings
- Michelle R. GriffinDirectorNamed in SEC Form D filings
- Molly W. HoultDirectorNamed in SEC Form D filings
- Peter BisgaardDirectorNamed in SEC Form D filings
- Shaun B. McMeansExecutive OfficerNamed in SEC Form D filings
- Simeon GeorgeDirectorNamed in SEC Form D filings
- Timothy JohnsonExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 24- PendingEpitranscriptome EvaluationUSPTOApplication 18687476
- GrantedMethod Of Direct Target Sequencing Using Nuclease ProtectionUSPTOUS 12,104,206
- GrantedMethods For Subtyping Diffuse Large B-cell Lymphoma (dlbcl)USPTOUS 11,384,399
Show all 24 patent records
- Epitranscriptome EvaluationDec 26, 2024 · Application 18687476Pending
- Method Of Direct Target Sequencing Using Nuclease ProtectionOct 1, 2024 · US 12,104,206Granted
- Methods For Subtyping Diffuse Large B-cell Lymphoma (dlbcl)Jul 12, 2022 · US 11,384,399Granted
- Methods Of Detecting Dna And Rna In The Same SampleApr 7, 2022 · Application 17416982Pending
- Methods Of Detecting Gene FusionsMar 8, 2022 · US 11,268,133Granted
- Nuclease Protection Methods For Detection Of Nucleotide VariantsSep 19, 2017 · US 9,765,385Granted
- Methods Of Co-detecting Mrna And Small Non-coding RnaDec 6, 2016 · US 9,512,469Granted
- Methods For Detecting Nucleic AcidsSep 15, 2016 · Application 15034831Pending
- Subtyping Lung CancersJan 21, 2016 · Application 14772038Pending
- Quantitative Nuclease Protection Assay (qnpa) And Sequencing (qnps) ImprovementsAug 21, 2014 · Application 14266884Pending
- Compositions And Methods For Alk Molecular TestingOct 31, 2013 · Application 13856390Pending
- Method Of Direct Target Sequencing Using Nuclease ProtectionApplication 62435459Pending
- Methods For Subtyping Diffuse B-cell Lymphoma (dlbcl)Application PCTUS2016054501Pending
- Method Of Direct Target Sequencing Using Nuclease ProtectionApplication PCTUS2017017512Pending
- Method Of Direct Target Sequencing Using Nuclease ProtectionApplication 62294143Pending
- Methods Of Detecting Dna And Rna In The Same SampleApplication 62787114Pending
- Methods Of Detecting Dna And Rna In The Same SampleApplication PCTUS2019064041Pending
- Epitranscriptome EvaluationApplication 63239703Pending
- Compounds That Inhibit METTL3 And Methods Of Making And Using The SameApplication 63435673Pending
- Subtyping Lung CancersApplication PCTUS2014019967Pending
- Methods For Detecting Nucleic AcidsApplication 61900225Pending
- Nuclease Protection Methods For Detection Of Nucleotide VariantsApplication PCTUS2013048610Pending
- Nuclease Protection Methods For Detection Of Nucleotide VariantsApplication 61829102Pending
- Compounds For Use In The Treatment Of Cancer And Methods Of Making And Using The SameApplication PCTUS2023086244Pending
Related companies, and why
- Akron Biotechnology, LLCSimilar federal contract value in Biotech · $1.2M in contracts
- Ultima Genomics, Inc.Similar federal contract value in Biotech · $1.2M in contracts
- VIRTICI LLCSimilar federal contract value in Biotech · $1.2M in contracts
- EXTEND BIOSCIENCES INCSimilar federal contract value in Biotech · $1.1M in contracts
- ORBIS BIOSCIENCES, INC.Similar federal contract value in Biotech · $1.1M in contracts
- PARABON COMPUTATION, INC.Similar federal contract value in Biotech · $1.1M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .